Anúncio
Anúncio

DMAC

DMAC logo

DiaMedica Therapeutics Inc. Common Stock

8.16
USD
Patrocinado
-0.19
-2.29%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

8.16

0.00
+0.01%

Relatórios de Lucros DMAC

Rácio de surpresa positiva

DMAC separação 20 de 28 últimas estimativas.

71%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.18
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+5.88%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
--

DiaMedica Therapeutics Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, DMAC reported earnings of -0.17 USD per share (EPS) for Q3 25, missing the estimate of -0.16 USD, resulting in a -4.17% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -14.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -0.18 USD, with revenue projected to reach -- USD, implying an aumentar of 5.88% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, DiaMedica Therapeutics Inc. Common Stock reported EPS of -$0.17, missing estimates by -4.17%, and revenue of $0.00, 0% as expectations.
The stock price moved down -14.1%, changed from $6.31 before the earnings release to $5.42 the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on 6 analistas, DiaMedica Therapeutics Inc. Common Stock is expected to report EPS of -$0.18 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio